

## **Electronic supplementary information (ESI)**

### **Polymeric nanovesicle as simultaneous delivery platform with Doxorubicin conjugation and Elacridar encapsulation for enhanced treatment of multidrug-resistant breast cancer**

Hong Xiao, Jin He, Xiaoxia Li, Bo Li, Lu Zhang, Yong Wang,\* Du Cheng, and Xintao Shuai\*

PCFM Lab of Ministry of Education, School of Materials Science and Engineering, Sun Yat-sen University, Guangzhou 510275, China

### **Synthesis of methoxy-poly(ethylene glycol)-poly( $\beta$ -benzyl-L-aspartate) (mPEG-PBLA)**

Firstly,  $\epsilon$ -benzyloxycarbonyl-L-aspartic acid N-carboxyanhydride (BLA-NCA) was synthesized as previously reported.<sup>1</sup> Then the diblock polymer mPEG-PBLA was prepared by ring-opening polymerization of BLA-NCA according to our previous literature.<sup>2</sup> Briefly, mPEG-NH<sub>2</sub> (0.33 g, 0.33 mmol) was vacuum dried at 70 °C for 2 h and dissolved in 50 mL of anhydrous CH<sub>2</sub>Cl<sub>2</sub>. Then, BLA-NCA (2.49 g, 10 mmol) dissolved in anhydrous DMF (5.0 mL) was added into the solution under N<sub>2</sub> atmosphere and the mixture was stirred at 35 °C for 48 h. mPEG-PBLA was purified by precipitation in diethyl ether (1 L) for three times. The product was obtained as a white sticky solid after vacuum drying. (Yield: 85.64%, Mn = 7150 Da calculated from <sup>1</sup>H NMR analysis)

### **Synthesis of methoxy-poly(ethylene glycol)-poly(N-(6-hydroxyhexyl)-L-aspartamide- $\beta$ -benzyl-L-aspartate) (mPEG-P[Asp(HPA)-BLA])**

Ammonolysis reaction of mPEG-PBLA was conducted as reported before.<sup>3</sup> Briefly, mPEG-PBLA (0.80 g, 0.12 mmol) was dissolved in anhydrous DMF (10 mL), then

5-amino-1-pentanol (0.5 equiv. to the residual benzyl ester groups in mPEG-PBLA) was added into the solution and the reaction was kept at 35 °C for 24 h. The mixture solution was dialyzed (molecular weight cut off (MWCO): 3.5 kDa) against methanol for 24 h and precipitated in diethyl ether twice to obtain the polymer mPEG-P[Asp(HPA)-BLA]. (Yield: 54.28%,  $M_n$  = 7075 Da calculated from  $^1\text{H}$  NMR analysis)

### **Synthesis of 3-(4-methyl-2,5-dioxo-2,5-dihydrofuran-3-yl) propanoic acid (CDM) conjugated polymer (mPEG-P[Asp(HPA-g-CDM)-BLA])**

The chlorine-substituted CDM was synthesized according to reported methods.<sup>4-6</sup> Briefly, 3-(4-methyl-2,5-dioxo-2,5-dihydrofuran-3-yl) propanoic acid (0.276 g, 1.5 mmol) was dissolved in 10 mL dry dichloromethane, and then oxalyl chloride (0.378 g, 3 mmol) and a catalytic amount of DMF (40  $\mu\text{L}$ ) were added on an ice-cold bath under  $\text{N}_2$  protection. The solution was stirred for 15 minutes at 0 °C, and then transferred to room temperature for an additional 1 h. The solvent was rotary evaporated and then the residue was re-dissolved in 20 mL  $\text{CH}_2\text{Cl}_2$  and repeat the evaporation procedure for three times to remove excess oxalyl chloride. The chlorine-substituted CDM was obtained as a yellowish oil and used directly without further purification.

Then the chlorine-substituted CDM (200 mg, 0.99 mmol) was reacted with mPEG-P[Asp(HPA)-BLA] (400 mg, 5.7  $\mu\text{mol}$ ) in 5 mL dry dichloromethane with 30  $\mu\text{L}$  of fresh distilled TEA as acid-capturer. The reaction was proceeded at 35 °C for 24 h under  $\text{N}_2$  atmosphere and the solution was then precipitated in diethyl ether twice. The product was collected by centrifugation and vacuum dried to obtain mPEG-P[Asp(HPA-g-CDM)-BLA]. (Yield: 82.86%,  $M_n$  = 9560 Da calculated from  $^1\text{H}$  NMR analysis)


### **Conjugation of DOX to the polymer**

50 mg DOX HCl, 10  $\mu\text{L}$  fresh distilled TEA and 200 mg polymer were dissolved in 4 mL anhydrous DMF and added into a 10 mL Schlenk-tube under  $\text{N}_2$  atmosphere. The


mixture solution was stirred at 35 °C for 24 h under dark condition. Subsequently, the mixture solution was dialyzed (MWCO: 3.5 kDa) against DMF to remove excess DOX and TEA, followed by precipitated in diethyl ether. The final product was obtained as a dark-red solid by centrifugation and vacuum drying. (Yield: 63.57%,  $M_n = 13600$  Da calculated from  $^1\text{H}$  NMR analysis)

### **Polymer Characterization**

$^1\text{H}$  NMR spectra were carried out on a Bruker 400 MHz spectrometer and  $\text{DMSO-}d_6$  was used as solvent. UV-Vis spectral measurements were recorded using Unico UV-2000 UV-Vis spectrophotometer. The fluorescence spectra were measured on a spectrofluorophotometer (Perkin Elmer Ltd., United Kingdom). The molecular weight distribution of polymers was analyzed using a gel permeation chromatography (GPC) system consisting of a Waters 1515 pump, an Ultrahydrogel<sup>TM</sup> 500 column, an Ultrahydrogel<sup>TM</sup> 250 column, and a Waters 2417 differential refractive index detector with PEG as a calibration standard. DMF containing LiBr (1.0 g/L) was used as an eluent at a flow rate of 1.0 mL/min.



**Fig. S1** Schematic illustration of the synthetic approaches for the acid-labile DOX-conjugated polymer.




**Fig. S2**  $^1\text{H}$  NMR spectra of the block polymers in  $\text{DMSO-}d_6$ : (A) PEG-PBLA, (B) mPEG-P[Asp(HPA)-BLA], (C) mPEG-P[Asp(HPA-g-CDM)-BLA], (D) mPEG-P[Asp(HPA-g-DOX)-BLA].


**Table S1.** Characteristics of block copolymers

Polymer	$M_w^a$ (kDa)	$M_w^b$ (kDa)	$M_w/M_n^b$
mPEG-P[Asp(HPA)-BLA]	7.0	8.5	1.21
mPEG-P[Asp(HPA-g-DOX)-BLA]	13.6	19.2	1.41


<sup>a</sup> calculated by  $^1\text{H}$  NMR; <sup>b</sup> calculated by GPC.




**Fig. S3** (A) Confocal laser scanning microscopic (CLSM) images of MCF-7 (A) and MCF-7/ADR (B) cells incubated with free DOX, DNVs and E-DNVs at 10  $\mu\text{g/mL}$  DOX concentration for 4 h. MCF-7/ADR cells were pre-treated with Ela for 12 h before transfection in With-Ela groups. Red fluorescence: DOX; blue fluorescence: nuclei stained with DAPI. The scale bars represent 20  $\mu\text{m}$ . DOX concentration if applied: 10  $\mu\text{g/mL}$ ; Ela concentration if applied: 0.5  $\mu\text{g/mL}$ . (C) Statistical data of intranuclear DOX fluorescence intensity in MCF-7/ADR cells after receiving the treatment of free DOX, free DOX + Ela, DNVs, DNVs + Ela and E-DNVs for 4 h and 8 h, respectively. \* $P < 0.05$  vs. free DOX and DNVs at the same incubation time.




**Fig. S4** The cell uptake of DOX in MCF-7/ADR cells detected using flow cytometry assay. MCF-7/ADR cells were co-cultured with free DOX, D-NVs, free DOX + Ela, DNVs + Ela and E-DNVs for 8 h. MCF-7/ADR cells were pre-treated with Ela for 12 h before transfection in free DOX + Ela and DNVs + Ela groups. DOX concentration if applied: 10  $\mu\text{g/mL}$ , Ela concentration if applied: 0.5  $\mu\text{g/mL}$ .



**Fig. S5** The viability of MCF-7 and MCF-7/ADR cells incubated with free DOX (A) and free Ela (B) on various concentration. (C) Detection of apoptotic MCF-7/ADR cells using Annexin V-FITC and DAPI flow cytometry assay. MCF-7/ADR cells were co-cultured with free Ela for 36 h. Ela concentration was 0.5  $\mu\text{g/mL}$ .




**Fig. S6** The P-gp fluorescence intensity was calculated from the immunofluorescent images of MCF-7/ADR cells incubated with different samples. \* $P < 0.05$  vs. free DOX and DNVs.




**Fig. S7** *In vivo* ICG fluorescence images of tumor bearing mice at different times after tail vein injection (A) and *ex vivo* ICG fluorescence images of the organs from the



same mouse (B). The tumors were excised at 24 h post-injection time. The animal models were the mice bearing MCF-7 tumor and MCF-7/ADR tumor. The images of the organs from the mouse bearing MCF-7/ADR tumor receiving equivalent saline solution showed no fluorescence in organs and tumor.



**Fig. S8** Tumor growth inhibition of various treatments in MCF-7 tumors (A). Tumor sizes were measured every 2 days ( $n = 6$ ). Means and standard errors were shown. The body weight of animals bearing MCF-7 tumors (B). The arrows pointed the drug administration time. \* $P < 0.05$  compared with PBS and free DOX, # $P < 0.05$  compared with PBS for MCF-7 tumor. DOX dose: 2.5 mg/kg body weight; Ela dose: 0.25 mg/kg body weight.



**Fig. S9** *Ex vivo* histological analyses of tumor sections excised from mice bearing

MCF-7 after various treatments. Nuclei were stained blue, and extracellular matrix and cytoplasm were stained red in H&E staining. In TUNEL assay, brown and green stains indicated apoptotic and normal cells, respectively (A). H&E staining images of the heart of tumor-bearing mice after various treatments (B). DOX dose: 2.5 mg/kg body weight; Ela dose: 0.25 mg/kg body weight. Scale bars were 50  $\mu$ m.

## Notes and references

1. J. Li, T. Wang, D. Wu, X. Zhang, J. Yan, S. Du, Y. Guo, J. Wang and A. Zhang, *Biomacromolecules*, 2008, **9**, 2670-2676.
2. W. Chen, Y. Yuan, D. Cheng, J. Chen, L. Wang and X. Shuai, *Small*, 2014, **10**, 2678-2687.
3. L. Zhang, H. Xiao, J. Li, D. Cheng and X. Shuai, *Nanoscale*, 2016, **8**.
4. C.-Y. Sun, S. Shen, C.-F. Xu, H.-J. Li, Y. Liu, Z.-T. Cao, X.-Z. Yang, J.-X. Xia and J. Wang, *J. Am. Chem. Soc.*, 2015, **137**, 15217-15224.
5. H.-J. Li, J.-Z. Du, X.-J. Du, C.-F. Xu, C.-Y. Sun, H.-X. Wang, Z.-T. Cao, X.-Z. Yang, Y.-H. Zhu, S. Nie and J. Wang, *P. Natl. Acad. Sci. U. S. A.*, 2016, **113**, 4164-4169.
6. T. Suma, J. Cui, M. Muellner, Y. Ju, J. Guo, M. Hu and F. Caruso, *ACS Macro Lett.*, 2015, **4**, 160-164.